
    
      In Part A, study therapy will be administered as separate products, each taken q.d. by mouth.
      In Part B and Part C, participants will take 2 uprifosbuvir (+) grazoprevir (+) ruzasvir FDC
      tablets q.d. by mouth; each uprifosbuvir (+) grazoprevir (+) ruzasvir FDC tablet contains
      grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg.
    
  